Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

• Revenue in USD (TTM)49.35m
• Net income in USD-1.13m
• Incorporated2011
• Employees36.00

• Location
  Fennec Pharmaceuticals Inc68 Tw Alexander DrPO Box 13628RESEARCH TRIANGLE PARK 27709United StatesUSA
• Phone+1 (919) 636-4530
• Fax+1 (919) 890-0490
• Websitehttps://fennecpharma.com/